USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
10 Aug 2021 | 02:45 PM GMT

Masterclass: DTx Reimbursement in the US

Participants:

Armin Furtwaengler Global Medical Lead Innovation Scouting Boehringer Ingelheim International GmbH
Armin Furtwaengler
Global Medical Lead Innovation Scouting Boehringer Ingelheim International GmbH
Chris Wasden Chief Strategy OfficerTwill
Chris Wasden
Chief Strategy OfficerTwill
Cyndi Williams SVP Strategic OperationsDojo
Cyndi Williams
SVP Strategic OperationsDojo
Emily Lewis Global Digital Transformation LeadUCB
Emily Lewis
Global Digital Transformation LeadUCB
Jaydev Thakkar Chief Operations OfficerBiofourmis
Jaydev Thakkar
Chief Operations OfficerBiofourmis
JC
Jennifer Cook Team Lead, Global Market Access Respiratory Boehringer Ingelheim
JC
Jennifer Cook
Team Lead, Global Market Access Respiratory Boehringer Ingelheim
Jim Howard CEOReadout Health
Jim Howard
CEOReadout Health
Joseph Rubinsztain CEOChronWell
Joseph Rubinsztain
CEOChronWell
LV
Lauren van den Heuvel Associate director, innovative solutionsOtsuka Pharmaceutical
LV
Lauren van den Heuvel
Associate director, innovative solutionsOtsuka Pharmaceutical
Mike Pace Founder & CEOPalmHealthCo
Mike Pace
Founder & CEOPalmHealthCo
Rick Bartels President/Founder DTxCC
Rick Bartels
President/Founder DTxCC
Stanton Sugarman Lead Commercial OperationsGAIA AG
Stanton Sugarman
Lead Commercial OperationsGAIA AG
Vasyl Pyrozhyk Vice PresidentSMBC
Vasyl Pyrozhyk
Vice PresidentSMBC

About this Meeting

Even though showing evidence and getting regulatory approval are important to build successful DTx tools, getting paid for these is crucial in order to thrive. While there are some commercialization models that might work, like D2C or partnerships with pharma, getting reimbursed by public and private payers will be critical to reach the levels of adoption needed for higher revenues from DTx products. Join us in this US-focused interactive masterclass led by Happify Health where we will talk about: 

  •  What are the drivers for payers to reimburse DTx products/services? Any differences in requirements between CMS & private payers? 
  •  Payers’ requirements and best practices to meet their expectations. 
  •  Role of Pharmacy Benefit Managers (PBMs) as an entry point for DTx reimbursement - is being included in their formularies enough?
  •  Role of CPT and HCPCS codes: paying physicians for their use of DTx in the practice of medicine.